Chinese hamster ovary (CHO) cells are being pushed to their productivity limits in drug development and biomanufacturing. Biopharmaceutical companies working on promising new therapies increasingly struggle with development challenges such as weak protein expression, low-yield purification steps, and poorly optimized analytical techniques. To address those challenges, innovators need robust cell-expression platforms and advanced process, analytical, and biomanufacturing technologies. Since 2012, KBI Biopharma has performed development and/or manufacturing services using more than 20 different cell lines generated by Selexis SA. In…